Overview

Feasibility Test of Folic Acid on Acute Kidney Injury

Status:
NOT_YET_RECRUITING
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the feasibility of folic acid supplementation as a treatment for adult patients with acute kidney injury (AKI) receiving hospital care. The main question it aims to answer is: Is it feasible to conduct a fully-powered randomized controlled trial (RCT) to assess the efficacy and safety of folic acid supplementation in AKI management? Researchers will compare two groups (usual care vs. usual care + 5 mg folic acid) to determine the feasibility of folic acid supplementation and estimate the sample size required for a fully powered RCT. Participants will: 1. Receive either usual care, or usual care combined with oral folic acid (5 mg daily) until AKI resolution (up to 30 days); 2. Undergo regular monitoring during hospitalization and follow-ups at 3 months and one year post-discharge.
Phase:
EARLY_PHASE1
Details
Lead Sponsor:
The University of Hong Kong
Collaborator:
Queen Mary Hospital, Hong Kong
Treatments:
Folic Acid